

Minutes of the 2025 Annual General Shareholders' Meeting

Meeting Format:

Visual communication assisted shareholders meeting (meeting convened physically, supplemented by video conference)

Time: 9:00 a.m., Monday, May 26, 2025

Physical shareholders' meeting venue:

4F, G Building, No. 3-1, Yuanqu St., Nangang District, Taipei City

Video conference platform:

Taiwan Depository & Clearing Corporation "Stock Services Platform" – eMeeting platform (URL: <https://stockservices.tdcc.com.tw>)

Countermeasures for postponing or reconvening the meeting if the Platform or participation in the virtual meeting is obstructed due to natural disasters, accidents or other force majeure events: Please refer to the meeting notice for details; NA.

Attendance:

The number of shares represented by shareholders attending the meeting in person or by proxy was 49,791,111 shares, which accounted for 58.76% of the 84,724,899 shares issued by the Company.

Chairperson: Shu-Fang Ou, Chairperson of the Board of Directors

Recorder: Yu-Chiao Sun

Members Present:

Director Pi-Jung Lin, Director Tsan-Der Chou, Director Su-Hei Weng, Director Hong-Jen Chang, Independent Director Min-Zhi Xiao, Independent Director Vincent Liu, Independent Director Yun-Hua Yang, Independent Director Wei-Ju Chen, General Manager Kenneth Lu, Finance and Accounting Director Yu-Chiao Sun, CPA of Deloitte & Touche Nai-Hua Kuo and Attorney of ERIK International Law Office Tung-Yuan Chiang. All directors of the company attended the meeting.

I. 【Announcement of the Commencement of the Meeting】 The aggregate shareholding of the shareholders present in person or by proxy constituted a quorum. The Chairperson called the meeting to order.

II. 【Chairperson's Address】 (Omitted)

III. 【Matters to be Reported】

1. The 2024 business report is submitted for your review.

Description:

Please refer to Appendix 1 for the Company's 2024 business report.

2. The 2024 final accounts report reviewed by the Audit Committee is submitted for your review.

Description:

Please refer to Appendix 2 for the final accounts report reviewed by the Audit Committee of the Company.

3. The report on the distribution status of 2024 employee compensation and director remuneration is submitted for your review.

Description:

The distribution amount of employee compensation was NT\$41,314,974, and the distribution amount of director remuneration was NT\$17,111,487, accounting for 3.00% and 1.24% respectively of the profit before tax and before distribution deduction of employee and director remuneration, both of which were paid in cash and were not different from the estimated amounts recorded in the accounts.

4. The report on the distribution status of 2024 cash dividends is submitted for your review.

Description:

As approved by the Board of Directors on March 6, 2025, the Company shall distribute cash dividends to shareholders in the amount of NT\$635,436,743 out of the distributable earnings for the year 2024, with each share being distributed with a dividend of NT\$7.5, distributed on April 21, 2025.

5. The report on the investment status in Mainland China is submitted for your review. Please refer to the Proceedings Manual of the Meeting.
6. The report on the status of undertaking the endorsement and guarantee is submitted for your review.

Description:

As of March 31, 2025, the status of the endorsement and guarantees the Company provided to the subsidiaries in accordance with the “Procedures for Endorsement and Guarantee” is set out in the table below.

No.	Guarantee	Relationship to this Company	Financing institution	Guaranteed amount		Actual amount borrowed	
				Currency	Amount (thousand)	Currency	Amount (thousand)
1	Kunshan Universal Trading Co., Ltd.	70% owned subsidiary of the company	Bank SinoPac	USD	3,000	USD	-

Note: The above amount does not exceed the specified limit.

7. The report on the Company's 2024 director remuneration is submitted for your review

Description:

- (1) The relationships between the distribution policy, standard and combination, and procedures for the remuneration of the Company with business performance and future risks:
 - I. Article 25-1 of the Company's Articles of Incorporation authorizes the Board of Directors to determine director remuneration according to the level of each director's participation in the operation and the value of their contribution, and take into account the domestic standards of the same trade. Additionally, in accordance with Article 30 of the Articles of Incorporation, if there are any remaining profits in the prevailing year, no more than 3% of the prevailing year's profits may be distributed as director remuneration.
 - II. Director remuneration is regularly evaluated in accordance with the Rules for Performance Evaluation of Board of Directors. The major evaluation items are comprehensively considered for director remuneration as follows:
 - i. Business performance: Comprehensively references factors from this year including the 8% growth of the operating revenue and the 3% increase of the pre-tax net profits.

- ii. Annual rating: References the Company being ranked among the top 5% of TPEX-listed companies in the Corporate Governance Evaluation, and the results of Board of Directors and functional committee annual performance evaluations, all of which were remarkably outstanding.
- iii. Peer level: References the average level of director remuneration provided by the peer TPEX listed companies.

The above results indicate the sound overall operation and excellent performance of the Company's Board of Directors.

- III. The director remuneration for this year accounts for 2.30% of net profit after tax. The actual amount of director remuneration paid this year was reviewed by the Compensation Committee and then resolved upon by the Board of Directors.
- IV. The distribution policy for the director remuneration of the Company is positively related to the operating performance and future risks. The rationality of director remuneration is regularly evaluated by both the Compensation Committee and the Board of Directors. In addition to considering individual directors' individual responsibilities and contributions, the Company's overall operating performance, industrial development trends and future risks are also considered as the criteria for determining the payment; the remuneration system is also reviewed in a timely manner in accordance with relevant laws and regulations to improve the efficiency of the board's operations.

- (2) The details of the individual director remuneration are shown on the following page:

Unit: Thousand NT\$

Position	Name	Remuneration to Directors								The sum of A, B, C and D and proportion to net profit after tax		Remuneration to the capacity as employees								The sum of A, B, C, D, E, F and G and proportion to net profit after tax		Remuneration received from an invested company other than the company's subsidiary or parent company
		Remuneration (A)		Pension (B)		Remuneration to directors (C) (Note 1)		Business execution expenses (D)				Salaries, bonus and special disbursement(E)		Pension (F)		Remuneration to employees (G)						
		The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company	All companies mentioned in the financial statements	The Company		All companies mentioned in the financial statements		The Company	All companies mentioned in the financial statements	
																Cash	Stock	Cash	Stock			
Chairperson	Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang	2,184	2,184	-	-	2,390	2,390	60	60	4,634 0.44%	4,634 0.44%	-	-	-	-	-	-	-	-	4,634 0.44%	4,634 0.44%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung	-	-	-	-	2,390	2,390	60	60	2,450 0.23%	2,450 0.23%	962	962	58	58	-	-	-	-	3,470 0.33%	3,470 0.33%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der	-	-	-	-	2,390	2,390	60	60	2,450 0.23%	2,450 0.23%	-	-	-	-	-	-	-	-	2,450 0.23%	2,450 0.23%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei	-	-	-	-	2,390	2,390	60	60	2,450 0.23%	2,450 0.23%	-	-	-	-	-	-	-	-	2,450 0.23%	2,450 0.23%	None
Director	Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen (Note 2)	-	-	-	-	1,593	1,593	40	40	1,633 0.15%	1,633 0.15%	-	-	-	-	-	-	-	-	1,633 0.15%	1,633 0.15%	None
Independent Director	Xiao Min-Zhi	900	900	-	-	1,490	1,490	60	60	2,450 0.23%	2,450 0.23%	-	-	-	-	-	-	-	-	2,450 0.23%	2,450 0.23%	None
Independent Director	Liu Vincent	900	900	-	-	1,490	1,490	60	60	2,450 0.23%	2,450 0.23%	-	-	-	-	-	-	-	-	2,450 0.23%	2,450 0.23%	None
Independent Director	Yang Yun-Hua	900	900	-	-	1,490	1,490	60	60	2,450 0.23%	2,450 0.23%	-	-	-	-	-	-	-	-	2,450 0.23%	2,450 0.23%	None
Independent Director	Chen Wei-Ru (Note 2)	600	600	-	-	993	993	40	40	1,633 0.15%	1,633 0.15%	-	-	-	-	-	-	-	-	1,633 0.15%	1,633 0.15%	None
Independent Director	Chen Yan-Jun (Note 3)	300	300	-	-	496	496	20	20	816 0.08%	816 0.08%	-	-	-	-	-	-	-	-	816 0.08%	816 0.08%	None

Note 1: The 2024 director remuneration was an estimate.

Note 2: Newly appointed on June 19, 2024.

Note 3: Dismissed on June 19, 2024.

IV. 【Matters for Acknowledgment】

Agenda 1 (proposed by the Board of Directors)

Proposal: The 2024 business report and financial statements are submitted for acknowledgment.

Description:

1. The audit of the Company's 2024 financial statements and consolidated financial statements has been completed by the certified public accountant Kuo Nai-Hua and the certified public accountant Chen Chung-Cheng from Deloitte & Touche, and a written audit report has been issued.
2. For the 2024 business report, certified public accountant's audit report, and the aforementioned financial statements, please refer to Appendix 1 and Appendixes 3-4.
3. Please acknowledge the proposal.

Resolution: The proposal was approved and the voting results were as follows:

Shares present at the time of voting: 49,791,111

Voting Results	% of the total shares present
Votes in favor: 49,555,992 (Electronic votes: 8,061,941 ; Virtual votes: 0)	99.52%
Votes against: 59,882 (Electronic votes: 59,882 ; Virtual votes: 0)	0.12%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained: 175,237 (Electronic votes: 88,306 ; Virtual votes: 1,699)	0.35%

Agenda 2 (proposed by the Board of Directors)

Proposal: The 2024 Statement of the Distribution of Earnings is submitted for acknowledgment.

Description:

1. The review of the Company's 2024 Statement of the Distribution of Earnings had been completed by the Audit Committee and submitted to the Board of Directors for approval.
2. For the 2024 Statement of the Distribution of Earnings, please refer to Appendix 5.
3. Please acknowledge the proposal.

Resolution: The proposal was approved and the voting results were as follows:

Shares present at the time of voting: 49,791,111

Voting Results	% of the total shares present
Votes in favor: 49,546,348 (Electronic votes: 8,052,347 ; Virtual votes: 0)	99.50%
Votes against: 75,601 (Electronic votes: 75,601 ; Virtual votes: 0)	0.15%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained: 169,162 (Electronic votes: 82,181 ; Virtual votes: 1,699)	0.33%

V. 【Matters for Discussion】

Agenda 1 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Articles of Incorporation is submitted for deliberation.

Description:

1. In response to the amendments to the laws and regulations, it is proposed to revise some provisions of the Company's Articles of Incorporation. For the comparison table of the provisions before and after the revision, please refer to Appendix 6.
2. Please deliberate on this matter.

Resolution: The proposal was approved and the voting results were as follows:

Shares present at the time of voting: 49,791,111

Voting Results	% of the total shares present
Votes in favor: 49,540,614 (Electronic votes: 8,046,613 ; Virtual votes: 0)	99.49%
Votes against: 84,726 (Electronic votes: 84,726 ; Virtual votes: 0)	0.17%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained: 165,771 (Electronic votes: 78,790 ; Virtual votes: 1,699)	0.33%

Agenda 2 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Procedures for Acquisition or Disposal of Assets is submitted for deliberation.

Description:

1. In response to the Company's operational needs, it is proposed to revise some provisions of the Company's Procedures for Acquisition or Disposal of Assets. For the comparison table of the provisions before and after the revision, please refer to Appendix 7.
2. Please deliberate on this matter.

Resolution: The proposal was approved and the voting results were as follows:

Shares present at the time of voting: 49,791,111

Voting Results	% of the total shares present
Votes in favor: 49,539,470 (Electronic votes: 8,045,469 ; Virtual votes: 0)	99.49%
Votes against: 81,508 (Electronic votes: 81,508 ; Virtual votes: 0)	0.16%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained: 170,133 (Electronic votes: 83,152 ; Virtual votes: 1,699)	0.34%

Agenda 3 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Procedures for Lending Funds to Other Parties is submitted for deliberation.

Description:

1. In response to the Company's practical operational needs, it is proposed to revise some provisions of the Company's Procedures for Lending Funds to Other Parties. For the comparison table of the provisions before and after the revision, please refer to Appendix 8.
2. Please deliberate on this matter.

Resolution: The proposal was approved and the voting results were as follows:

Shares present at the time of voting: 49,791,111

Voting Results	% of the total shares present
Votes in favor: 49,482,524 (Electronic votes: 7,988,523 ; Virtual votes: 0)	99.38%

Voting Results	% of the total shares present
Votes against: 103,654 (Electronic votes: 103,654 ; Virtual votes: 0)	0.20%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained: 204,933 (Electronic votes: 117,952 ; Virtual votes: 1,699)	0.41%

Agenda 4 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Rules of Procedure for Shareholders Meetings is submitted for deliberation.

Description:

1. In response to the Company's practical operational needs, it is proposed to revise some provisions of the Company's Rules of Procedure for Shareholders Meetings. For the comparison table of the provisions before and after the revision, please refer to Appendix 9.
2. Please deliberate on this matter.

Resolution: The proposal was approved and the voting results were as follows:

Shares present at the time of voting: 49,791,111

Voting Results	% of the total shares present
Votes in favor: 48,360,933 (Electronic votes: 6,866,932 ; Virtual votes: 0)	97.12%
Votes against: 1,269,403 (Electronic votes: 1,269,403 ; Virtual votes: 0)	2.54%
Votes invalid: 0 (Electronic votes: 0 ; Virtual votes: 0)	0.00%
Votes abstained: 160,775 (Electronic votes: 73,794 ; Virtual votes: 1,699)	0.32%

VI. 【Extraordinary Motions】 None.

VII. 【Adjournment】 9:26 a.m., Monday, May 26, 2025

There are no shareholders' questions at this shareholders' meeting.

Appendix 1

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 2024 Business Report

1. Operating Status in 2024

(1) Operating results:

The Group's consolidated operating revenue in 2024 was NT\$4,228,302 thousand, an increase of 3.58% over the previous year; consolidated net profit attributable to the Company's owners of the parent was NT\$1,064,721 thousand, an increase of NT\$19,627 thousand or 1.88% over the previous year.

The independent operating revenue of the parent company in Taiwan was NT\$3,513,460 thousand in 2024, an increase of 8.42% over the previous year, and the parent company's operating revenue accounted for 83.09% of the Group's consolidated operating revenue. In Taiwan (including Penghu), there were 31 self-owned eyewear stores, contributing sales revenue of NT\$840,819 thousand, making up 23.93% of the total operating revenue and representing a year-on-year increase of 14.70%. With a total of 28 partner clinics, the income generated from brand licensing, technical services, consulting, and rental to the clinics was NT\$2,202,494 thousand, accounting for 62.69% of the total operating revenue and representing a year-on-year increase of 6.42%. The income from medical supplies was NT\$470,147 thousand, accounting for 13.38% of the total operating revenue and representing a year-on-year increase of 7.36%.

(2) Budget implementation status:

The Company's internal budget for the year 2024 had been approved by the Board of Directors, but the financial forecast has not been disclosed to the public. The overall operating condition was good.

(3) Profitability analysis:

		Unit: Thousand NT\$	
Item \ Year		2024	2023
Financial revenue and expenditure	Net consolidated operating revenue	4,228,302	4,082,256
	Consolidated gross profit	2,533,286	2,448,370
	Consolidated net profit attributable to owners of the parent	1,064,721	1,045,094
Profitability	Consolidated return on assets (%)	19.59	22.35
	Consolidated return on shareholders' equity (%)	29.59	34.48
	Consolidated gross margin (%)	24.84	26.06
	Consolidated earnings per share (NT\$)	12.57	12.34

(4) Research and development status:

In recent years, the Company has continued to introduce advanced ophthalmic technologies and equipment, including femtosecond laser assisted cataract surgery and SMILE Pro, the next-generation of SMILE Laser Vision Correction. In 2024, the Company further introduced SMILE Pro 2.0, featuring an enhanced AI tracking function, along with a new type of intraocular lens designed to minimize glare. In addition, the Company has supported its partner clinics by providing training and implementation programs related to these new technologies, which have been highly praised by the medical teams of the partner clinics. Such efforts have significantly optimized surgical efficiency and service quality, offering partner clinics more advanced medical options and enhancing the overall brand reputation through positive word-of-mouth recognition.

Furthermore, adhering to the business philosophy of providing high-quality products to the public, the Company established a cross-disciplinary team integrating biotechnology and food science to jointly develop “Universal Gold Lutein”, an eye nutrition supplement suitable for the entire family. The raw materials and manufacturing processes are subject to strict quality control, with formulations specifically tailored to meet the nutritional needs of seniors, adults, and children. In response to the demands of modern digital lifestyles, the Company launched a new “SOS Enhanced” formula, offering comprehensive solutions for maintaining visual clarity and moisture. Since its launch, “Universal Gold Lutein” has received numerous prestigious awards, including the “SNQ Award”, “National Biotechnology and Medical Care Quality Award”, “National Brand Yushan Award”, “Taiwan Excellent Manufacturer Award”, “National Biotechnology Award”, “Monde Selection Gold Quality Award”, and “iTQi Superior Taste Award”. These accolades highlight the Company's unwavering commitment to quality and dedication to safeguarding public health.

2. Summary of Business Plan for 2025

(1) Management Policy and Operation Objectives

A. Ophthalmology market

(a) Laser vision correction market

The laser vision correction market has experienced rapid growth in recent years, with increasing acceptance among the general public. At the end of 2022, the Company introduced SMILE Pro, the next-generation laser vision correction surgery, which features a minimally invasive procedure that reduces dry-eye symptoms while offering enhanced comfort, speed, and safety. This technology has helped partner clinics provide their customers with comprehensive and high-quality vision correction solutions. In 2025, the Company plans to roll out a full range of SMILE, SMILE Pro, and SMILE Pro 2.0 services as part of its market differentiation strategy. In addition to existing refractive laser technologies, the Company has also introduced and developed PresbyLASIK and myopia laser technology equipment for its partner clinics to address the increasing demand from the presbyopic

population. At the same time, the Company is preparing to introduce new implantable contact lens (ICL) technology, offering an optimal solution for patients with high myopia who are unsuitable candidates for corneal laser surgery. Following the introduction of this technology, partner clinics will be able to offer a more comprehensive range of vision correction services.

(b) Cataract market

The Company has continued to support its partner clinics in promoting advanced technologies and applications for femtosecond laser-assisted cataract surgery combined with premium intraocular lens (IOL) selections. This approach offers the advantages of precision medicine and superior post-operative visual outcomes, assisting partner clinics in continuously increasing the adoption rate of the femtosecond laser-assisted cataract procedure. In addition, the Company has introduced a new type of intraocular lens featuring reduced glare and extended depth of focus, further enhancing patient satisfaction with cataract surgery.

(c) Dry-eye treatment market

Demand in the dry eye treatment market is substantial, as many contact lens users, middle-aged individuals, and seniors require ongoing care. Moreover, continuous dry eye management is often necessary following laser vision correction and cataract surgeries. Since 2022, the Company has gradually introduced the dry eye treatment program and equipment into its partner clinics, and patient acceptance has steadily increased over the past two years. It is anticipated that, as patient satisfaction continues to spread through word of mouth, the service volume will grow progressively in the coming years.

B. Optometry market

(a) Innovative technology and precise services: The e-Universal brand leading the Optometry Sector

Leveraging innovative technology, the Company launched “i-Precision Intelligent Prescription”, which integrates 21 examination steps and 21 myopia management measures. The Company is the first to deploy multi-focal stress relief experience equipment from Japan's Hoya and France's Essilor across all our stores, in combination with Zeiss iCM positioning systems, fully automated optometry devices, AI technology, and big data analytics. Together, these solutions provide consumers with a fully personalized, precise, and comfortable eyewear fitting experience. Adhering to the core philosophy of “Medical Optometry, Scientific Eyewear Prescription,” the Company delivers bespoke eyewear solutions for each customer. Our products blend professional expertise, fashion sensibility, and technological innovation, setting us apart from traditional optical retailers and fast-fashion eyewear prescription models. Looking ahead, the Company will continue to strengthen its offerings in myopia control products, senior wellness service packages, lutein eye health supplements and personalized product services, aiming to drive steady growth in both revenue and profitability.

(b) Big Vision Project: Comprehensive eye health management

By integrating the technological strengths and equipment of partner clinics with the Company's self-operated optical stores, the Company actively promotes the importance of myopia control and axial length tracking among school-age children. Through technological innovation and AI applications, the Company continues to introduce advanced optometry equipment and regularly updates a diverse range of myopia control products to enhance customer engagement among students and their parents. Centered around the philosophy of "Lifelong Eye Health Solutions for the Entire Family," the Company has integrated optometry services, myopia prevention and control, and related solutions under the e-Universal brand, establishing itself as the first choice for consumers. This strategy not only strengthens the brand's market value but also delivers comprehensive and reliable eye health solutions to an expanding consumer base.

(2) Important production and marketing strategies

A. Marketing strategy

The Company actively establishes long-term strategic partnerships with major optical and biotechnology corporations, both domestically and internationally, to integrate resource advantages and jointly drive innovation and application in optical products and technologies. Concurrently, the Company continues to invite its partner clinics to participate in public welfare initiatives, integrating professional services with corporate social responsibility. Through these efforts, the Company promotes public awareness of vision health and hygiene, thereby naturally cultivating good habits for healthy eye care among the public.

B. Brand strategy

Centering on the "e-Universal" brand, the Company integrates Taiwan's leading ophthalmic medical and optometric services to provide a comprehensive one-stop solution through its physical retail channels. To further enhance the customer experience, the Company has launched an exclusive e-commerce platform for prescription eyewear and eye care products, achieving seamless integration between online and offline services. This not only serves a broad online customer base but also drives traffic to physical stores. To achieve long-term development objectives, the Company continues to optimize its operational structure and enhance the per-store productivity of its existing locations. Additionally, by leveraging the channel resources of partner clinics and implementing cross-marketing strategies, the Company is comprehensively strengthening its brand impact. Through continuous innovation and professional excellence, the Company is committed to leading the market and achieving its goal of becoming the leading brand in Taiwan's vision optics industry.

(3) Impact of external competitive environment, regulatory environment, and overall business environment

While pursuing corporate growth and achieving operational goals, the Company incorporates ESG (environmental, social, governance) corporate sustainability into our corporate strategies and operations. Through the gradual implementation of ESG initiatives, the Company is committed to sustainable management practices aimed at enhancing service quality and creating long-term corporate value.

In the 10th Corporate Governance Evaluation in 2024, the Company was ranked among the “Top 5% of TPEX-listed Companies” for a second straight year; receiving the highest honor as a “Top 10% of Non-financial/electronic TWSE/TPEX-listed Companies with a Market Value of NT\$10 Billion or Above” for the first time; and performed outstandingly in the four aspects of protecting shareholder rights and interests, strengthening board structure and operations, improving information transparency, and promoting sustainable development. In 2023, the Company was included in Morgan Stanley Capital International (MSCI) ESG A Ratings for the first time, and was subsequently upgraded to AA in 2024. In terms of overall sustainability performance, the Company participated in the 17th Taiwan Corporate Sustainability Awards (TCSA) competition for the first time, and achieved excellent results: a Bronze Award in Sustainability Report-Service Industry Category 1, and an Excellence Award in the Comprehensive Performance-Taiwan Sustainable Enterprise category. In addition, the Company was recognized as a “2024 Outstanding Business Operator” by the Ministry of Finance and received the “TPEX-Listed Medium-Size Partner Award” by the Taipei Exchange. These affirmed the Company’s ongoing contributions to the market through ethical corporate governance and outstanding operational performance.

The Company remains vigilant to changes in the competitive environment, the regulatory environment, and the macroeconomy in order to mitigate potential impact on its operations. In 2024, the Company continued to optimize cyber security by conducting advocacy and training courses on “Information Security”, “Personal Data Protection Act” and “Trade Secrets Act”; put in place information security supervisors and information security personnel; and obtained an iPAS “Information Security Engineer” competency certification and the ISO/IEC 27001:2022 Information Security Management System (ISMS) Lead Auditor training certification. Although the Company’s operations are characterized by low carbon emissions, it actively responds to climate change initiatives by establishing environmental management systems and goals in line with government policies. The Company collaborates closely with supply chain partners to fulfill its commitment to environmental sustainability. Furthermore, the Company has actively promoted “Green Procurement”, prioritizing products with green certifications, and has continuously invested in energy-saving equipment, resulting in a steady year-over-year decline in both total electricity consumption and energy intensity.

The Company fully recognizes its responsibilities and mission to society. Through active participation in public welfare initiatives, investments in the care of disadvantaged groups, emphasis on talent development and community building, and support for domestic cultural advancement, the Company aims to leverage its corporate influence to drive positive social change. In 2024, the Company continued its core initiatives, including vision health awareness activities, charitable eyewear donations, and educational programs promoting eye health. The Company also fully sponsored employee participation in a 1,000-person blood donation drive and the “Love the Earth” charity run held at Neihu Technology Park, demonstrating tangible engagement with the local community. Moreover, the Company actively supports the development of Taiwan’s cultural and creative industries by sponsoring and investing in the creation, production, broadcasting, and performance of works by domestic performing arts groups, cultural organizations, and individual artists across film, television, music, and theater. These efforts align with government policies and contribute to the overall advancement of Taiwan’s cultural and creative sectors.

(4) Future Development Strategy

Universal Vision Biotechnology Co., Ltd. (“UVB”) upholds the corporate philosophy inspired by the “Great Learning”—to manifest one’s bright virtue, to love the people, and to pursue the highest good. Staying aligned with the times, UVB remains committed to continuously introducing cutting-edge medical technologies and advanced technical equipment. We are dedicated to assisting partner clinics in enhancing high-quality medical services and achieving greater customer satisfaction, while integrating our self-operated eyewear stores to deliver fully customized services and products. Striving for excellence, our mission is to pursue the perfect clarity and comfort of vision for every pair of eyes, and to create moments of customer delight and lasting value.

Going forward, UVB will continue to expand distribution channels and develop service platforms, aiming to enable people to “See Clear, See Comfort, See the Future!” Guided by this motto, we will carry on the mission to capture emerging trends in the biotechnology and vision care industries, striving to become a source of pride for Taiwan in the global vision biotechnology industry. We look forward to working together with all stakeholders and wish everyone good health and a prosperous future.

Chairperson: Ou Shu-Fang

General Manager: Lu Kenneth

Accounting Manager: Sun Yu-Chiao

Appendix 2

Audit Committee Review Report

The 2024 business report, financial statements (including parent company only financial statements and consolidated financial statements), the earnings distribution proposal, etc., among which the audit of the financial statements have been completed by the certified public accountants Kuo Nai-Hua and Chen Chung-Cheng from Deloitte & Touche Accounting Firm, who also issued the audit report. The review of the aforementioned business report, financial statements and earnings distribution statement have been completed by the Audit Committee, which believes that there is no inconsistency. This report is hereby made in accordance with the provisions of Article 14-4 of the Securities and Exchange Act as well as Article 219 of the Company Act, and is submitted for your review.

Submitted to

2025 General Shareholders' Meeting of Universal Vision Biotechnology Co., Ltd.

Convener of Audit Committee: Xiao Min-Zhi

March 6, 2025

Appendix 3

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Universal Vision Biotechnology Co., Ltd.

Opinion

We have audited the accompanying parent company only financial statements of Universal Vision Biotechnology Co., Ltd. (the “Company”), which comprise the parent company only balance sheets as of December 31, 2024 and 2023, and the parent company only statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the parent company only financial statements, including material accounting policy information (collectively referred to as the “parent company only financial statements”).

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2024 and 2023, and its parent company only financial performance and its parent company only cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements for the year ended December 31, 2024. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter of for the Company's financial statements for the year ended December 31, 2024 is described stated as follows:

Ophthalmology Business Division - Accuracy of Technical Service Revenue

The Company's ophthalmology business division 2024 operating revenue - technical service revenue is the main revenue and is growing year by year, which has a significant impact on independent financial statements; thus, we listed the accuracy of ophthalmology business division -

technical service revenue as a key audit matter. For additional information on the accounting policy of revenue recognition, refer to Note 4.m. to the financial statements.

We have performed principal audit procedures for confirming the accuracy of the ophthalmology business division - technical service revenue as below:

1. We obtained an understanding of the design and tested the implementation effectiveness of internal control of the ophthalmology business division - technical service revenue.
2. We obtained the subsidiary ledger of the ophthalmology business division - technical service revenue and examined the contents, checked the contracts, relevant supporting documents and the collection of receivables to confirm the authenticity of the recognized technical service revenue.

Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision, and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the year ended December 31, 2024 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Nai-Hua Kuo and Chung-Cheng Chen.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 6, 2025

Notice to Readers

The accompanying parent company only financial statements are intended only to present the financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such parent company only financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying parent company only financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and parent company only financial statements shall prevail.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY BALANCE SHEETS DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

ASSETS	2024		2023	
	Amount	%	Amount	%
CURRENT ASSETS				
Cash and cash equivalents (Notes 4 and 6)	\$ 93,414	2	\$ 603,315	13
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	1,295,373	24	-	-
Financial assets at amortized cost - current (Notes 4, 9 and 10)	24,000	-	578,363	12
Trade receivables (Notes 4, 11 and 23)	506,811	9	514,450	11
Trade receivables from related parties (Notes 4, 11 and 30)	7,189	-	5,629	-
Other receivables (Note 30)	9,255	-	1,644	-
Inventories (Notes 4 and 12)	255,774	5	253,911	5
Other current assets	<u>35,107</u>	<u>1</u>	<u>31,876</u>	<u>1</u>
Total current assets	<u>2,226,923</u>	<u>41</u>	<u>1,989,188</u>	<u>42</u>
NON-CURRENT ASSETS				
Financial assets at fair value through other comprehensive income - non-current (Notes 4, 8 and 10)	111,073	2	-	-
Investments accounted for using the equity method (Notes 4 and 13)	527,848	10	574,932	12
Property, plant and equipment (Notes 4, 14 and 31)	1,578,576	29	1,362,436	29
Right-of-use assets (Notes 4 and 15)	858,064	16	644,402	14
Intangible assets (Notes 4 and 16)	4,263	-	3,401	-
Deferred tax assets (Notes 4 and 25)	54,990	1	43,803	1
Prepayments for equipment	-	-	82,386	2
Refundable deposits	<u>33,085</u>	<u>1</u>	<u>28,543</u>	<u>-</u>
Total non-current assets	<u>3,167,899</u>	<u>59</u>	<u>2,739,903</u>	<u>58</u>
TOTAL	<u>\$ 5,394,822</u>	<u>100</u>	<u>\$ 4,729,091</u>	<u>100</u>
LIABILITIES AND EQUITY				
CURRENT LIABILITIES				
Short-term borrowings (Notes 17 and 31)	\$ 50,000	1	\$ -	-
Trade payables (Note 18)	225,754	4	269,235	6
Payables for equipment (Note 20)	90,614	2	87,279	2
Other payables (Note 19)	228,258	4	215,509	4
Current tax liabilities (Notes 4 and 25)	143,900	3	153,747	3
Lease liabilities - current (Notes 4 and 15)	143,982	3	123,212	3
Other current liabilities (Note 23)	<u>21,052</u>	<u>-</u>	<u>20,150</u>	<u>-</u>
Total current liabilities	<u>903,560</u>	<u>17</u>	<u>869,132</u>	<u>18</u>
NON-CURRENT LIABILITIES				
Deferred tax liabilities (Notes 4 and 25)	47,053	1	38,060	1
Lease liabilities - non-current (Notes 4 and 15)	750,713	14	551,148	12
Long-term accounts payable (Note 20)	70,908	1	92,574	2
Guarantee deposits	<u>575</u>	<u>-</u>	<u>535</u>	<u>-</u>
Total non-current liabilities	<u>869,249</u>	<u>16</u>	<u>682,317</u>	<u>15</u>
Total liabilities	<u>1,772,809</u>	<u>33</u>	<u>1,551,449</u>	<u>33</u>
EQUITY (Note 22)				
Share capital				
Ordinary shares	<u>847,249</u>	<u>16</u>	<u>847,249</u>	<u>18</u>
Capital surplus	<u>381,924</u>	<u>7</u>	<u>381,924</u>	<u>8</u>
Retained earnings				
Legal reserve	378,623	7	278,614	6
Special reserve	11,384	-	5,042	-
Unappropriated earnings	<u>1,998,328</u>	<u>37</u>	<u>1,676,197</u>	<u>35</u>
Total retained earnings	<u>2,388,335</u>	<u>44</u>	<u>1,959,853</u>	<u>41</u>
Other equity	<u>4,505</u>	<u>-</u>	<u>(11,384)</u>	<u>-</u>
Total equity	<u>3,622,013</u>	<u>67</u>	<u>3,177,642</u>	<u>67</u>
TOTAL	<u>\$ 5,394,822</u>	<u>100</u>	<u>\$ 4,729,091</u>	<u>100</u>

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2024		2023	
	Amount	%	Amount	%
OPERATING REVENUE (Notes 4, 23 and 30)	\$ 3,513,460	100	\$ 3,240,692	100
OPERATING COSTS (Notes 12 and 24)	<u>(1,361,200)</u>	<u>(39)</u>	<u>(1,270,538)</u>	<u>(39)</u>
GROSS PROFIT	<u>2,152,260</u>	<u>61</u>	<u>1,970,154</u>	<u>61</u>
OPERATING EXPENSES (Notes 21 and 24)				
Selling and marketing expenses	(433,851)	(12)	(375,713)	(12)
General and administrative expenses	(302,812)	(9)	(316,842)	(10)
Expected credit loss	<u>-</u>	<u>-</u>	<u>(4,227)</u>	<u>-</u>
Total operating expenses	<u>(736,663)</u>	<u>(21)</u>	<u>(696,782)</u>	<u>(22)</u>
PROFIT FROM OPERATIONS	<u>1,415,597</u>	<u>40</u>	<u>1,273,372</u>	<u>39</u>
NON-OPERATING INCOME AND EXPENSES				
Interest income (Note 24)	36,248	1	14,759	1
Other income (Notes 24 and 30)	7,263	-	6,498	-
Other gains and losses (Note 24)	(97,333)	(3)	(1,148)	-
Finance costs (Note 24)	(15,697)	-	(10,030)	-
Share of loss or profit of subsidiaries, associates and joint ventures (Note 4)	<u>(27,339)</u>	<u>(1)</u>	<u>2,305</u>	<u>-</u>
Total non-operating income and expenses	<u>(96,858)</u>	<u>(3)</u>	<u>12,384</u>	<u>1</u>
PROFIT BEFORE INCOME TAX	1,318,739	37	1,285,756	40
INCOME TAX EXPENSE (Notes 4 and 25)	<u>(254,018)</u>	<u>(7)</u>	<u>(240,662)</u>	<u>(8)</u>
NET PROFIT FOR THE YEAR	<u>1,064,721</u>	<u>30</u>	<u>1,045,094</u>	<u>32</u>
OTHER COMPREHENSIVE INCOME (LOSS)				
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translation of the financial statements of foreign operations (Note 22)	23,420	1	(7,936)	-
Unrealized loss on investments in debt instruments at fair value through other comprehensive income (Note 22)	(3,559)	-	-	-
Income tax relating to items that may be reclassified subsequently to loss or profit (Notes 4 and 25)	<u>(3,972)</u>	<u>-</u>	<u>1,587</u>	<u>-</u>
Other comprehensive income (loss) for the year, net of income tax	<u>15,889</u>	<u>1</u>	<u>(6,349)</u>	<u>-</u>
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	<u>\$ 1,080,610</u>	<u>31</u>	<u>\$ 1,038,745</u>	<u>32</u>
EARNINGS PER SHARE (Note 26)				
Basic	<u>\$ 12.57</u>		<u>\$ 12.34</u>	
Diluted	<u>\$ 12.53</u>		<u>\$ 12.31</u>	

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

	Share Capital		Capital Surplus	Retained Earnings			Other Equity		Total Equity
	Shares (In Thousands)	Amount		Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translating of the Financial Statements of Foreign Operations	Unrealized Valuation Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income	
BALANCE AT JANUARY 1, 2023	79,929	\$ 799,292	\$ 381,924	\$ 193,575	\$ 10,367	\$ 1,284,172	\$ (5,035)	\$ -	\$ 2,664,295
Appropriation of 2022 earnings									
Legal reserve	-	-	-	85,039	-	(85,039)	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(479,575)	-	-	(479,575)
Share dividends distributed by the Company	4,796	47,957	-	-	-	(47,957)	-	-	-
Reversal of special reserve	-	-	-	-	(5,325)	5,325	-	-	-
Changes in the Company's ownership interests in subsidiaries (Note 13)	-	-	-	-	-	(45,823)	-	-	(45,823)
Net profit for the year ended December 31, 2023	-	-	-	-	-	1,045,094	-	-	1,045,094
Other comprehensive loss for the year ended December 31, 2023, net of income tax	-	-	-	-	-	-	(6,349)	-	(6,349)
Total comprehensive income (loss) for the year ended December 31, 2023	-	-	-	-	-	1,045,094	(6,349)	-	1,038,745
BALANCE AT DECEMBER 31, 2023	84,725	847,249	381,924	278,614	5,042	1,676,197	(11,384)	-	3,177,642
Appropriation of 2023 earnings									
Legal reserve	-	-	-	100,009	-	(100,009)	-	-	-
Special reserve	-	-	-	-	6,342	(6,342)	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(593,074)	-	-	(593,074)
Changes in the Company's ownership interests in subsidiaries (Note 13)	-	-	-	-	-	(43,165)	-	-	(43,165)
Net profit for the year ended December 31, 2024	-	-	-	-	-	1,064,721	-	-	1,064,721
Other comprehensive income (loss) for the year ended December 31, 2024, net of income tax	-	-	-	-	-	-	18,736	(2,847)	15,889
Total comprehensive income (loss) for the year ended December 31, 2024	-	-	-	-	-	1,064,721	18,736	(2,847)	1,080,610
BALANCE AT DECEMBER 31, 2024	84,725	\$ 847,249	\$ 381,924	\$ 378,623	\$ 11,384	\$ 1,998,328	\$ 7,352	\$ (2,847)	\$ 3,622,013

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	\$ 1,318,739	\$ 1,285,756
Adjustments for:		
Depreciation expense	408,802	348,135
Amortization expense	2,731	3,651
Expected credit loss recognized on trade receivables	-	4,227
Net loss on fair value changes of financial assets at fair value through profit or loss	100,222	-
Finance costs	15,697	10,030
Interest income	(36,248)	(14,759)
Share of loss (profit) of subsidiaries, associates and joint ventures	27,339	(2,305)
Loss on disposal of property, plant and equipment	5,296	1,373
Gain on disposal of intangible assets	-	(16)
Write-down of inventories	1,000	480
Net unrealized gain on foreign currency exchange	(1,155)	-
Gain and relief from lease modifications	(572)	(1,015)
Changes in operating assets and liabilities		
Trade receivables	7,639	165
Trade receivables from related parties	(1,560)	(4,183)
Other receivables	(352)	(320)
Inventories	(2,863)	(99,944)
Other current assets	(3,231)	(3,876)
Trade payables	(43,481)	52,736
Other payables	12,579	14,872
Other current liabilities	902	1,949
Cash generated from operations	1,811,484	1,596,956
Interest received	28,701	14,617
Interest paid	(3,307)	(618)
Income taxes paid	(270,031)	(210,749)
Net cash generated from operating activities	<u>1,566,847</u>	<u>1,400,206</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at fair value through other comprehensive income	(113,521)	-
Purchase of financial assets at amortized cost	-	(4,733)
Proceeds from sale of financial assets at amortized cost	554,363	-
Purchase of financial assets at fair value through profit or loss	(1,395,595)	-
Acquisition of associate	-	(140,000)
Payments for property, plant and equipment	(424,791)	(360,299)
Proceeds from disposal of property, plant and equipment	181	79
Increase in refundable deposits	(5,319)	(62)
Payments for intangible assets	(2,325)	(1,253)
Proceeds from disposal of intangible assets	-	70
Increase in prepayments for equipment	-	(59,972)
Dividend received	-	618
Net cash used in investing activities	<u>(1,387,007)</u>	<u>(565,552)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	50,000	-
Proceeds from guarantee deposits received	40	-
Repayments of the principal portion of lease liabilities	(146,707)	(132,871)
Dividends paid to owners of the Company	(593,074)	(479,575)
Net cash used in financing activities	<u>(689,741)</u>	<u>(612,446)</u>
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	<u>(509,901)</u>	<u>222,208</u>
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	<u>603,315</u>	<u>381,107</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	<u>\$ 93,414</u>	<u>\$ 603,315</u>

The accompanying notes are an integral part of the parent company only financial statements.

Appendix 4

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Universal Vision Biotechnology Co., Ltd.

Opinion

We have audited the accompanying consolidated financial statements of Universal Vision Biotechnology Co., Ltd. and its subsidiaries (collectively referred to as the “Group”), which comprise the consolidated balance sheets as of December 31, 2024 and 2023, and the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the “consolidated financial statements”).

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2024 and 2023, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the year ended December 31, 2024. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter of for the Group's consolidated financial statements for the year ended December 31, 2024 is described stated as follows:

Ophthalmology Business Division - Accuracy of Technical Service Revenue

The Group's ophthalmology business division 2024 operating revenue - technical service revenue is the main revenue and is growing year by year, which has a significant impact on the consolidated financial statements; thus, we listed the accuracy of ophthalmology business division - technical service revenue as a key audit matter. For additional information on the accounting policy of revenue recognition, refer to Note 4.n. to the consolidated financial statements.

We have performed principal audit procedures for confirming the accuracy of the ophthalmology business division - technical service revenue as below:

1. We obtained an understanding of the design and tested the implementation effectiveness of internal control of the ophthalmology business division - technical service revenue.
2. We obtained the subsidiary ledger of the ophthalmology business division - technical service revenue and examined the contents, checked the contracts, relevant supporting documents and the collection of receivables to confirm the authenticity of the recognized technical service revenue.

Other Matter

We have also audited the parent company only financial statements of Universal Vision Biotechnology Co., Ltd. as of and for the years ended December 31, 2024 and 2023 on which we have issued an unmodified opinion.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended December 31, 2024 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Nai-Hua Kuo and Chung-Cheng Chen.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 6, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

ASSETS	2024		2023	
	Amount	%	Amount	%
CURRENT ASSETS				
Cash and cash equivalents (Notes 4 and 6)	\$ 506,854	9	\$ 1,062,545	21
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	1,295,373	22	-	-
Financial assets at amortized cost - current (Notes 4, 9 and 10)	115,216	2	578,363	11
Trade receivables (Notes 4, 11 and 23)	565,569	10	584,252	11
Other receivables (Note 25)	11,897	-	2,165	-
Inventories (Notes 4 and 12)	289,725	5	294,521	6
Other current assets	<u>57,187</u>	<u>1</u>	<u>58,030</u>	<u>1</u>
Total current assets	<u>2,841,821</u>	<u>49</u>	<u>2,579,876</u>	<u>50</u>
NON-CURRENT ASSETS				
Financial assets at fair value through other comprehensive income - non-current (Notes 4, 8 and 10)	111,073	2	-	-
Property, plant and equipment (Notes 4, 14 and 32)	1,756,259	31	1,592,350	31
Right-of-use assets (Notes 4 and 15)	917,162	16	731,066	14
Intangible assets (Notes 4 and 16)	22,790	-	22,981	1
Deferred tax assets (Notes 4 and 25)	72,259	1	67,251	1
Prepayments for equipment	-	-	94,085	2
Refundable deposits (Note 32)	41,202	1	39,093	1
Other non-current assets (Note 32)	<u>136</u>	<u>-</u>	<u>3,882</u>	<u>-</u>
Total non-current assets	<u>2,920,881</u>	<u>51</u>	<u>2,550,708</u>	<u>50</u>
TOTAL	<u>\$ 5,762,702</u>	<u>100</u>	<u>\$ 5,130,584</u>	<u>100</u>
LIABILITIES AND EQUITY				
CURRENT LIABILITIES				
Short-term borrowings (Notes 17 and 32)	\$ 92,012	2	\$ 8,670	-
Trade payables (Note 18)	268,070	5	312,308	6
Payables for equipment (Note 20)	91,080	1	93,036	2
Other payables (Note 19)	277,453	5	260,815	5
Current tax liabilities (Notes 4 and 25)	154,445	3	162,567	3
Lease liabilities - current (Notes 4 and 15)	178,399	3	155,272	3
Current portion of long-term borrowings (Notes 17 and 32)	-	-	1,301	-
Other current liabilities (Note 23)	<u>29,265</u>	<u>-</u>	<u>29,119</u>	<u>1</u>
Total current liabilities	<u>1,090,724</u>	<u>19</u>	<u>1,023,088</u>	<u>20</u>
NON-CURRENT LIABILITIES				
Deferred tax liabilities (Notes 4 and 25)	60,930	1	58,386	1
Lease liabilities - non-current (Notes 4 and 15)	783,828	14	613,018	12
Long-term accounts payable (Note 20)	70,908	1	92,574	2
Guarantee deposits	<u>584</u>	<u>-</u>	<u>543</u>	<u>-</u>
Total non-current liabilities	<u>916,250</u>	<u>16</u>	<u>764,521</u>	<u>15</u>
Total liabilities	<u>2,006,974</u>	<u>35</u>	<u>1,787,609</u>	<u>35</u>
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 22)				
Share capital				
Ordinary shares	<u>847,249</u>	<u>15</u>	<u>847,249</u>	<u>17</u>
Capital surplus	<u>381,924</u>	<u>7</u>	<u>381,924</u>	<u>7</u>
Retained earnings				
Legal reserve	378,623	6	278,614	5
Special reserve	11,384	-	5,042	-
Unappropriated earnings	<u>1,998,328</u>	<u>35</u>	<u>1,676,197</u>	<u>33</u>
Total retained earnings	<u>2,388,335</u>	<u>41</u>	<u>1,959,853</u>	<u>38</u>
Other equity	<u>4,505</u>	<u>-</u>	<u>(11,384)</u>	<u>-</u>
Total equity attributable to owners of the Company	3,622,013	63	3,177,642	62
NON-CONTROLLING INTERESTS	<u>133,715</u>	<u>2</u>	<u>165,333</u>	<u>3</u>
Total equity	<u>3,755,728</u>	<u>65</u>	<u>3,342,975</u>	<u>65</u>
TOTAL	<u>\$ 5,762,702</u>	<u>100</u>	<u>\$ 5,130,584</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2024		2023	
	Amount	%	Amount	%
OPERATING REVENUE (Notes 4 and 23)	\$ 4,228,302	100	\$ 4,082,256	100
OPERATING COSTS (Notes 12 and 24)	<u>(1,695,016)</u>	<u>(40)</u>	<u>(1,633,886)</u>	<u>(40)</u>
GROSS PROFIT	<u>2,533,286</u>	<u>60</u>	<u>2,448,370</u>	<u>60</u>
OPERATING EXPENSES (Notes 21 and 24)				
Selling and marketing expenses	(726,754)	(17)	(704,486)	(17)
General and administrative expenses	(406,181)	(10)	(427,670)	(11)
Expected credit loss	<u>(2,444)</u>	<u>-</u>	<u>(4,363)</u>	<u>-</u>
Total operating expenses	<u>(1,135,379)</u>	<u>(27)</u>	<u>(1,136,519)</u>	<u>(28)</u>
PROFIT FROM OPERATIONS	<u>1,397,907</u>	<u>33</u>	<u>1,311,851</u>	<u>32</u>
NON-OPERATING INCOME AND EXPENSES				
Interest income (Note 24)	39,576	1	19,158	-
Other income (Note 24)	8,117	-	8,069	-
Other gains and losses (Note 24)	(106,611)	(3)	(4,666)	-
Finance costs (Note 24)	<u>(20,948)</u>	<u>-</u>	<u>(15,833)</u>	<u>-</u>
Total non-operating income and expenses	<u>(79,866)</u>	<u>(2)</u>	<u>6,728</u>	<u>-</u>
PROFIT BEFORE INCOME TAX	1,318,041	31	1,318,579	32
INCOME TAX EXPENSE (Notes 4 and 25)	<u>(267,816)</u>	<u>(6)</u>	<u>(254,555)</u>	<u>(6)</u>
NET PROFIT FOR THE YEAR	<u>1,050,225</u>	<u>25</u>	<u>1,064,024</u>	<u>26</u>
OTHER COMPREHENSIVE INCOME (LOSS)				
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translation of the financial statements of foreign operations (Note 22)	30,233	-	(10,275)	-
Unrealized loss on investments in debt instruments at fair value through other comprehensive income (Note 22)	(3,559)	-	-	-
Income tax relating to items that may be reclassified subsequently to profit or loss (Notes 4 and 25)	<u>(3,972)</u>	<u>-</u>	<u>1,587</u>	<u>-</u>
Other comprehensive income (loss) for the year, net of income tax	<u>22,702</u>	<u>-</u>	<u>(8,688)</u>	<u>-</u>
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	<u>\$ 1,072,927</u>	<u>25</u>	<u>\$ 1,055,336</u>	<u>26</u>
NET PROFIT ATTRIBUTABLE TO:				
Owners of the Company	\$ 1,064,721	25	\$ 1,045,094	26
Non-controlling interests	<u>(14,496)</u>	<u>-</u>	<u>18,930</u>	<u>-</u>
	<u>\$ 1,050,225</u>	<u>25</u>	<u>\$ 1,064,024</u>	<u>26</u>
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:				
Owners of the Company	\$ 1,080,610	25	\$ 1,038,745	26
Non-controlling interests	<u>(7,683)</u>	<u>-</u>	<u>16,591</u>	<u>-</u>
	<u>\$ 1,072,927</u>	<u>25</u>	<u>\$ 1,055,336</u>	<u>26</u>
EARNINGS PER SHARE (Note 26)				
Basic	<u>\$ 12.57</u>		<u>\$ 12.34</u>	
Diluted	<u>\$ 12.53</u>		<u>\$ 12.31</u>	

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

	Equity Attributable to Owners of the Company						Other Equity		Non-controlling Interests (Note 27)	Total Equity
	Share Capital		Capital Surplus	Retained Earnings			Exchange Differences on Translating of the Financial Statements of Foreign Operations	Unrealized Valuation Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income		
	Shares (In Thousands)	Amount		Legal Reserve	Special Reserve	Unappropriated Earnings				
BALANCE AT JANUARY 1, 2023	79,929	\$ 799,292	\$ 381,924	\$ 193,575	\$ 10,367	\$ 1,284,172	\$ (5,035)	\$ -	\$ 165,019	\$ 2,829,314
Appropriation of 2022 earnings										
Legal reserve	-	-	-	85,039	-	(85,039)	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(479,575)	-	-	-	(479,575)
Share dividends distributed by the Company	4,796	47,957	-	-	-	(47,957)	-	-	-	-
Reversal of special reserve	-	-	-	-	(5,325)	5,325	-	-	-	-
Actual acquisition of interests in subsidiaries (Note 27)	-	-	-	-	-	(45,823)	-	-	(21,277)	(67,100)
Non-controlling interests	-	-	-	-	-	-	-	-	5,000	5,000
Net profit for the year ended December 31, 2023	-	-	-	-	-	1,045,094	-	-	18,930	1,064,024
Other comprehensive loss for the year ended December 31, 2023, net of income tax	-	-	-	-	-	-	(6,349)	-	(2,339)	(8,688)
Total comprehensive income (loss) for the year ended December 31, 2023	-	-	-	-	-	1,045,094	(6,349)	-	16,591	1,055,336
BALANCE AT DECEMBER 31, 2023	84,725	847,249	381,924	278,614	5,042	1,676,197	(11,384)	-	165,333	3,342,975
Appropriation of 2023 earnings										
Legal reserve	-	-	-	100,009	-	(100,009)	-	-	-	-
Special reserve	-	-	-	-	6,342	(6,342)	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(593,074)	-	-	-	(593,074)
Actual acquisition of interests in subsidiaries (Note 27)	-	-	-	-	-	(43,165)	-	-	(23,935)	(67,100)
Net profit for the year ended December 31, 2024	-	-	-	-	-	1,064,721	-	-	(14,496)	1,050,225
Other comprehensive income for the year ended December 31, 2024, net of income tax	-	-	-	-	-	-	18,736	(2,847)	6,813	22,702
Total comprehensive income (loss) for the year ended December 31, 2024	-	-	-	-	-	1,064,721	18,736	(2,847)	(7,683)	1,072,927
BALANCE AT DECEMBER 31, 2024	84,725	\$ 847,249	\$ 381,924	\$ 378,623	\$ 11,384	\$ 1,998,328	\$ 7,352	\$ (2,847)	\$ 133,715	\$ 3,755,728

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	\$ 1,318,041	\$ 1,318,579
Adjustments for:		
Depreciation expense	518,053	441,766
Amortization expense	3,437	4,380
Expected credit loss recognized on trade receivables	2,444	4,363
Net loss on fair value changes of financial assets at fair value through profit or loss	100,222	-
Finance costs	20,948	15,833
Interest income	(39,576)	(19,158)
Loss on disposal of property, plant and equipment	7,464	1,385
Costs transferred from property, plant, and equipment to expenses	1,332	-
Loss (gain) on disposal of intangible assets	1,452	(16)
Write-down of inventories	2,965	541
Net unrealized gain on foreign currency exchange	(1,155)	-
Gain and relief from lease modifications	(572)	(1,719)
Changes in operating assets and liabilities		
Trade receivables	16,103	(6,764)
Other receivables	(390)	(241)
Inventories	1,800	(89,849)
Other current assets	4,595	11,320
Trade payables	(44,238)	57,756
Other payables	16,499	16,241
Other current liabilities	146	2,496
Cash generated from operations	1,929,570	1,756,913
Interest received	31,080	18,850
Interest paid	(5,048)	(1,467)
Income taxes paid	(283,536)	(220,704)
Net cash generated from operating activities	<u>1,672,066</u>	<u>1,553,592</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at fair value through other comprehensive income	(113,521)	-
Purchase of financial assets at amortized cost	-	(1,743)
Proceeds from sale of financial assets at amortized cost	463,147	-
Purchase of financial assets at fair value through profit or loss	(1,395,595)	-
Payments for property, plant and equipment	(434,646)	(400,861)
Proceeds from disposal of property, plant and equipment	863	79
Increase in refundable deposits	(2,808)	(947)
Payments for intangible assets	(2,446)	(1,748)
Proceeds from disposal of intangible assets	-	70
Increase in other non-current assets	-	(130)
Increase in prepayments for equipment	-	(71,671)
Decrease in prepayments for equipment	878	-
Net cash used in investing activities	<u>(1,484,128)</u>	<u>(476,951)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	82,524	8,848
Repayments of long-term borrowings	(1,353)	(9,202)
Proceeds from guarantee deposits received	40	8
Repayments of the principal portion of lease liabilities	(184,076)	(168,633)
Dividends paid to owners of the Company	(593,074)	(479,575)
Acquisition of additional interests in subsidiaries	(67,100)	(67,100)
Changes in non-controlling interests	-	5,000
Net cash used in financing activities	<u>(763,039)</u>	<u>(710,654)</u>
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES	<u>19,410</u>	<u>(6,461)</u>
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	<u>(555,691)</u>	<u>359,526</u>
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	<u>1,062,545</u>	<u>703,019</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	<u>\$ 506,854</u>	<u>\$ 1,062,545</u>

The accompanying notes are an integral part of the consolidated financial statements.

Appendix 5

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

2024 Statement of the Distribution of Earnings

Unit: NT\$

Item	Amount	
Beginning undistributed earnings		\$976,772,396
Plus: Net profit after tax for the period		1,064,720,750
Less: Retained earnings adjusted due to investments accounted for using equity method (Note 1)		(43,165,094)
Less: Legal reserve allocation (10%)		(102,155,566)
Plus: Reversal and provision of special reserve in accordance with the law		11,383,526
Distributable earnings for the period		\$1,907,556,012
Distributable items (Note 2)		
Common share - cash dividend (NT\$7.5 per share)	(\$635,436,743)	(635,436,743)
Ending undistributed earnings		\$1,272,119,269

Note 1: Retained earnings adjusted due to the debit balance incurred from the change in shareholding ratio (without influencing control or without significant impact).

Note 2: The undistributed earnings in 2024 were prioritized for this distribution of earnings; and the dividend amount is calculated based on the current number of shares, which is 84,724,899 shares.

Chairperson: Ou Shu-Fang

General Manager: Lu Kenneth

Accounting Manager: Sun Yu-Chiao

Appendix 6

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. Comparison Table of Articles of Incorporation Before and After Revision

Article	After revision	Before revision	Description
Article 30	<p>The Company shall distribute 1% to 10% of the profit of the current year as employee compensation; <u>shall distribute no less than 10% of the said employee compensation to non-executive employees</u>; and shall distribute no more than 3% of the profit of the current year as director remuneration. However, if the Company still has accumulated losses, it shall make up for such losses.</p> <p>The employee compensation may be distributed in stock or cash, and the counterparty for such stock or cash may include employees of subordinate companies who meet certain conditions.</p> <p>The distribution of employee compensation <u>(including the compensation distribution ratio for non-executive employees)</u> and director remuneration shall be adopted by the Board of Directors with the attendance of two thirds or more of the directors and the consent of more than half of the directors in attendance, which shall be reported to the Shareholders Meeting.</p>	<p>The Company shall distribute 1% to 10% of the profit of the current year as employee compensation and shall distribute no more than 3% of the profit of the current year as director remuneration. However, if the Company still has accumulated losses, it shall make up for such losses.</p> <p>The employee compensation may be distributed in stock or cash, and the counterparty for such stock or cash may include employees of subordinate companies who meet certain conditions.</p> <p>The distribution of employee compensation and director remuneration shall be adopted by the Board of Directors with the attendance of two thirds or more of the directors and the consent of more than half of the directors in attendance, which shall be reported to the Shareholders Meeting.</p>	Revising the Articles of Incorporation in compliance with amendments to Paragraph 6, Article 14 of the Securities and Exchange Act, as well as FSC Order Chin-Kuan-Cheng-Fa-Tzu No. 1130385442.
Article 33	<p>These Articles of Incorporation were set up on July 11, 1994.</p> <p>The 1st amendment was made on February 15, 1996.</p> <p>The 2nd amendment was made on April 30, 1996.</p> <p>The 3rd amendment was made on March 31, 1997.</p> <p>The 4th amendment was made on August 3, 1998.</p> <p>The 5th amendment was made on November 19, 1999.</p> <p>The 6th amendment was made on December 11, 2001.</p> <p>The 7th amendment was made on February 21, 2002.</p> <p>The 8th amendment was made on May 21, 2002.</p> <p>The 9th amendment was made on July 30, 2002.</p> <p>The 10th amendment was made on June 2, 2003.</p> <p>The 11th amendment was made on May 31, 2005.</p>	<p>These Articles of Incorporation were set up on July 11, 1994.</p> <p>The 1st amendment was made on February 15, 1996.</p> <p>The 2nd amendment was made on April 30, 1996.</p> <p>The 3rd amendment was made on March 31, 1997.</p> <p>The 4th amendment was made on August 3, 1998.</p> <p>The 5th amendment was made on November 19, 1999.</p> <p>The 6th amendment was made on December 11, 2001.</p> <p>The 7th amendment was made on February 21, 2002.</p> <p>The 8th amendment was made on May 21, 2002.</p> <p>The 9th amendment was made on July 30, 2002.</p> <p>The 10th amendment was made on June 2, 2003.</p> <p>The 11th amendment was made on May 31, 2005.</p>	Added amendment date.

Article	After revision	Before revision	Description
	The 12 th amendment was made on June 14, 2006. The 13 th amendment was made on June 21, 2007. The 14 th amendment was made on June 24, 2010. The 15 th amendment was made on June 28, 2012. The 16 th amendment was made on June 17, 2015. The 17 th amendment was made on June 22, 2016. The 18 th amendment was made on June 14, 2018. The 19 th amendment was made on June 18, 2019. The 20 th amendment was made on June 15, 2020. The 21 st amendment was made on August 27, 2021. The 22 nd amendment was made on June 23, 2022. <u>The 23rd amendment was made on May 26, 2025.</u>	The 12 th amendment was made on June 14, 2006. The 13 th amendment was made on June 21, 2007. The 14 th amendment was made on June 24, 2010. The 15 th amendment was made on June 28, 2012. The 16 th amendment was made on June 17, 2015. The 17 th amendment was made on June 22, 2016. The 18 th amendment was made on June 14, 2018. The 19 th amendment was made on June 18, 2019. The 20 th amendment was made on June 15, 2020. The 21 st amendment was made on August 27, 2021. The 22 nd amendment was made on June 23, 2022.	

Appendix 7

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Comparison Table of Procedures for Acquisition or Disposal of Assets Before and After Revision

Article	After revision	Before Revision	Description
Article 10	<p>Authority for approval and decision making</p> <p>Before the Company acquires or disposes of assets specified in these Procedures, the office in charge of managing the Company's assets shall prepare all relevant assessment and necessary documents and consult with the relevant responsible departments.</p> <p><u>Approval for such acquisition or disposal shall be subject to the following authority:</u></p> <p><u>1. Securities</u></p> <p>(1) <u>For the acquisition or disposal of securities traded on a centralized trading market or over-the-counter market, where the amount per transaction or per day is NT\$300 million or less, shall be submitted through an internal sign-off process to the general manager and chairperson for approval; where the amount per transaction or per day is more than NT\$300 million but no more than NT\$500 million, the chairperson may be authorized to make the decision thereon and then report it to the next board meeting for retroactive confirmation; where the amount per transaction or per day exceeds NT\$500 million, it must be approved by the Board of Directors before it can be implemented.</u></p> <p>(2) <u>For the acquisition or disposal of securities not traded on a centralized trading market or over-the-counter market, where the transaction amount is 20% or less of the paid-in capital, an investment appraisal report shall be provided with such, then the whole must be submitted</u></p>	<p>Authority for approval and decision making</p> <p>Before the Company acquires or disposes of assets specified in these Procedures, the office in charge of managing the Company's assets shall prepare all relevant assessment and necessary documents and consult with the relevant responsible departments.</p> <p><u>After consultation on the acquisition or disposal proposal is completed, it shall be submitted to the general manager and chairperson for approval.</u></p>	<p>In compliance with corporate governance, revising the scope of authority for approval of and decision making on the acquisition or disposal of assets in these Procedures.</p>

Article	After revision	Before Revision	Description
	<p><u>through internal sign-off process to the general manager and chairperson for approval; where the transaction amount exceeds 20% of the paid-in capital, it must be approved by the Board of Directors before it can be implemented.</u></p> <p>2. Other assets</p> <p><u>For the acquisition or disposal of assets other than securities, where the transaction amount is 20% or less of the paid-in capital, it shall be submitted through internal sign-off process to the general manager and chairperson for approval; where the transaction amount exceeds 20% of the paid-in capital, it must be approved by the Board of Directors before it can be implemented.</u></p>		

Appendix 8

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Comparison Table of Procedures for Lending Funds to Other Parties Before and After Revision

Article	After revision	Before Revision	Description
Article 1	<p>The Company's <u>loaning of funds to others</u> shall be carried out in accordance with these Operational Procedures.</p> <p>Any matters not covered in these Procedures shall be handled in accordance with relevant laws and regulations.</p>	<p>The Company's <u>loaning of funds to other juristic persons other than shareholders (below, "borrowers" for short) for business needs</u> shall be carried out in accordance with these Operational Procedures.</p> <p>Any matters not covered in these Procedures shall be handled in accordance with relevant laws and regulations.</p>	Wording appropriately revised, in accordance with the applicable scope of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies.
Article 2	<p>Counterparties for loaning of funds</p> <ol style="list-style-type: none"> 1. Companies or businesses that have business dealings with the Company. 2. Other companies or businesses in which the Company has re-invested. 3. Companies or businesses in need of short-term financing. "Short term" as referred to here shall refer to one year. However, where a company's operating cycle is longer than one year, such an operating cycle shall prevail. The financing amount mentioned shall refer to the accumulated balance of the Company's short-term financing funds. 4. If the Company's responsible person violates the regulations in Paragraphs 1 <u>to 3</u>, he/she shall be jointly and severally liable for return of the funds together with the borrower; if the Company incurs damage, he/she shall also be liable for compensation for such damage. 	<p>Counterparties for loaning of funds</p> <ol style="list-style-type: none"> 1. Companies or businesses that have business dealings with the Company. 2. Other companies or businesses in which the Company has re-invested. 3. Companies or businesses in need of short-term financing. "Short term" as referred to here shall refer to one year. However, where a company's operating cycle is longer than one year, such an operating cycle shall prevail. <p>The financing amount mentioned <u>in the preceding paragraph</u> shall refer to the accumulated balance of the Company's short-term financing funds.</p> <p>If the Company's responsible person violates the <u>proviso to Paragraph 1</u>, he/she shall be jointly and severally liable for return of the funds together with the borrower; if the Company incurs damage, he/she shall also be liable for compensation for such damage.</p>	Wording revised as appropriate.
Article 4	<p>Total amount of funds loaned and loan limits for individual counterparties</p> <ol style="list-style-type: none"> 1. (Omitted) 2. (Omitted) 3. (Omitted) 	<p>Total amount of funds loaned and loan limits for individual counterparties</p> <ol style="list-style-type: none"> 1. (Omitted) 2. (Omitted) 3. (Omitted) 	Revisions made in accordance with Paragraph 4, Article 3 of the Regulations Governing Loaning of Funds and

Article	After revision	Before Revision	Description
	<p>4. When, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights, or when, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights and the Company itself, there is loaning of funds as required for financing, the total amount of funds loaned <u>shall not be subject to the limit of 20% of the net worth of the loaning company. However, the total amount of funds loaned and the loan limits for individual counterparties shall still be prescribed in its internal operational procedures in accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies formulated by the competent securities authority, and the loan period shall also be clearly specified therein.</u></p>	<p>4. When, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights, there is loaning of funds as required for financing, or when, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights and the Company itself, there is loaning of funds as required for financing, the total amount of funds loaned <u>shall not exceed 20% of the net worth of the loaning company, and the amount of funds loaned to an individual company shall not exceed 20% of the net worth of the loaning company. The financing period shall be limited to one year or one operating cycle.</u></p>	<p>Making of Endorsements/Guarantees by Public Companies, as well as revisions to wording as appropriate.</p>
Article 6	<p>Loan period and interest calculation method</p> <p>1. The loan period for any given loan shall not in principle exceed <u>one year</u>.</p> <p>2. The interest rate for the loaning of funds shall be no lower than the highest interest rate for the Company's short-term loans taken from financial institutions. The interest on the Company's loans shall in principle be calculated and paid on a monthly basis. In the event of special circumstances, adjustments may, with approval from the Board of Directors, be made in accordance with actual circumstances.</p>	<p>Loan period and interest calculation method</p> <p>1. The loan period for any given loan shall not in principle exceed <u>180 days. In the event of special circumstances, the loan period may, with the approval of the Board of Directors, be extended in accordance with actual circumstances.</u></p> <p>2. The interest rate for the loaning of funds shall be no lower than the highest interest rate for the Company's short-term loans taken from financial institutions. The interest on the Company's loans shall in principle be calculated and paid on a monthly basis. In the event of special circumstances, adjustments may, with approval from the Board of Directors, be made in accordance with actual circumstances.</p>	<p>The loan term is set to be no more than one year in principle, in accordance with the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies.</p>

Appendix 9

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Comparison Table of Rules of Procedure for Shareholders Meetings Before and After Revision

Article	After revision	Before Revision	Description
Article 3	<p>(Convening of Shareholders Meetings and meeting notices) (1. omitted)</p> <p><u>To convene a virtual shareholders meeting, the Company must implement it via a resolution with the attendance of two thirds of the directors and the consent of more than half of the directors in attendance.</u></p> <p>The Company shall prepare the electronic version of the meeting notice, proxy forms, as well as the cause of each agenda item and description materials relating to all proposals to the Shareholders Meeting, such as acknowledgment matters, discussion matters, and the selection or dismissal of directors, and upload them to the Market Observation Post System (MOPS) 30 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting; The Company shall also prepare the electronic version of the shareholders meeting handbook and supplemental meeting materials, and upload them to the MOPS 21 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting. In addition, 15 days prior to the date of a Shareholders Meeting, the Company shall also make available the handbook and supplemental meeting materials for that Shareholders Meeting for review by shareholders at any time. The meeting handbook and supplemental meeting materials shall also be displayed at the Company and its shareholder services agent.</p> <p><u>With regard to the meeting handbook and supplemental meeting materials mentioned in the preceding paragraph, the Company shall provide them to shareholders for reference in</u></p>	<p>(Convening of Shareholders Meetings and meeting notices) (1. omitted)</p> <p>The Company shall prepare the electronic version of the meeting notice, proxy forms, as well as the cause of each agenda item and description materials relating to all proposals to the Shareholders Meeting, such as acknowledgment matters, discussion matters, and the selection or dismissal of directors, and upload them to the Market Observation Post System (MOPS) 30 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting; The Company shall also prepare the electronic version of the shareholders meeting handbook and supplemental meeting materials, and upload them to the MOPS 21 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting. In addition, 15 days prior to the date of a Shareholders Meeting, the Company shall also make available the handbook and supplemental meeting materials for that Shareholders Meeting for review by shareholders at any time. The meeting handbook and supplemental meeting materials shall also be displayed at the Company and its shareholder services agent, <u>and be distributed on-site at the venue of the Shareholders Meeting.</u></p> <p>(Omitted below)</p>	<ol style="list-style-type: none"> 1. When the Company convenes a virtual shareholders meeting, shareholders may attend without a physical meeting. to protect the rights and interests of shareholders, Paragraph 2 is thus added, requiring such meetings to be implemented via a special resolution of the Board of Directors. 2. The original Paragraph 2 is relocated to Paragraph 3. 3. The original Paragraph 3 is relocated to Paragraph 5. Also, to allow shareholders to refer to the shareholders proceedings manual and supplementary meeting materials on the day of the shareholders meeting, regardless of whether they are participating in a physical shareholders meeting or doing so via video conference, the

Article	After revision	Before Revision	Description
	<p><u>the following manner on the day of the shareholders meeting:</u></p> <ol style="list-style-type: none"> <u>1. When convening a physical shareholders meeting, such materials shall be distributed onsite at the shareholders meeting.</u> <u>2. When convening a hybrid shareholders meeting, such materials shall be distributed onsite at the shareholders meeting as well as transmitted to the video conferencing platform in the form of electronic files.</u> <u>3. When convening a virtual shareholders meeting, the electronic files shall be transmitted to the video conferencing platform.</u> <p><u>(Omitted below)</u></p>		<p>numbering of this article is revised as appropriate, and Paragraph 4 is added.</p> <p>4. The original Paragraphs 4-9 are relocated to Paragraphs 6-11.</p>
Article 5	<p>(Principles for determining the venue and time of a Shareholders Meeting)</p> <p>(1. omitted)</p> <p><u>When convening a virtual shareholders meeting, the Company shall not be subject to the meeting venue limitations in the preceding paragraph.</u></p>	<p>(Principles for determining the venue and time of a Shareholders Meeting)</p> <p>(1. omitted)</p>	<p>Paragraph 2 is added to clearly state that, when convening a virtual shareholders meeting, the Company shall not be subject to limitations on meeting venue.</p>
Article 6	<p>(Preparation of documents such as the attendance book)</p> <p>(1. omitted)</p> <p>The time for accepting attendance registrations for shareholders shall be at least 30 minutes prior to the time the meeting commences. The place at which attendance registrations are accepted shall be clearly marked and a sufficient number of suitable personnel shall be assigned to handle the registrations. <u>For virtual shareholders meetings, the attendance registration shall be accepted on the shareholders meeting video conferencing platform at least 30 minutes prior to the time the meeting commences; shareholders that have completed the attendance registration shall be deemed to have attended the shareholders meeting in person.</u></p> <p>(3. to 6. omitted)</p>	<p>(Preparation of documents such as the attendance book)</p> <p>(1. omitted)</p> <p>The time for accepting attendance registrations for shareholders shall be at least 30 minutes prior to the time the meeting commences. The place at which attendance registrations are accepted shall be clearly marked and a sufficient number of suitable personnel shall be assigned to handle the registrations.</p> <p>(3. to 6. omitted)</p>	<ol style="list-style-type: none"> Paragraph 2 is hereby revised to clearly prescribe times and procedures for registrations with shareholders attending virtually. Paragraph 7 is hereby added, to allow shareholders attending the meeting via video conference the opportunity to read the meeting handbook, annual report, and other materials.

Article	After revision	Before Revision	Description
	<u>When convening a virtual shareholders meeting, the Company shall upload the meeting handbook, annual report and other meeting materials to the virtual meeting platform at least 30 minutes before the meeting starts, and keep this information disclosed until the end of the meeting.</u>		
Article 9	<p>The attendance at shareholders meetings shall be calculated based on the number of shares. The number of shares in attendance shall be calculated according to the number of shares indicated on the attendance book or the sign-in card handed in <u>as well as the ones registered on the video conferencing platform</u>, plus the number of shares whose voting rights are exercised by correspondence or electronically.</p> <p>The chair shall call the meeting to order at the scheduled meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement of the meeting, provided that no more than two such postponements may be made, with the combined postponed time not exceeding one hour in total. If, after two postponements, the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned due to lack of a quorum. <u>If the shareholders meeting is held virtually, the Company shall separately declare the meeting adjourned due to lack of quorum on the virtual meeting platform.</u></p> <p>If the quorum is not met after two postponements but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Paragraph 1, Article 175 of the Company Act, and all shareholders shall be notified of the tentative resolution and another Shareholders Meeting shall be convened within one month. <u>If the shareholders meeting is held virtually, shareholders that intend to attend the meeting</u></p>	<p>The attendance at Shareholders Meetings shall be calculated based on numbers of shares. The number of shares in attendance shall be calculated according to the number of shares indicated on the attendance book or the sign-in card handed in, plus the number of shares whose voting rights are exercised by correspondence or electronically.</p> <p>The chair shall call the meeting to order at the scheduled meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement of the meeting, provided that no more than two such postponements may be made, with the combined postponed time not exceeding one hour in total. If, after two postponements, the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned due to lack of a quorum.</p> <p>If the quorum is not met after two postponements but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Paragraph 1, Article 175 of the Company Act, and all shareholders shall be notified of the tentative resolution and another Shareholders Meeting shall be convened within one month.</p>	<p>1. Paragraph 1 is hereby revised, to clearly prescribe that if a shareholders meeting is convened virtually, the number of shares represented by shareholders having completed attendance registration via video conference shall be added to the calculation of the total number of shares in attendance.</p> <p>2. Paragraph 2 is hereby revised, to prescribe that if a shareholders meeting is convened virtually, then where the chair declares the meeting adjourned due to lack of a quorum, the Company shall also separately declare the meeting adjourned on the shareholders meeting video conferencing platform to inform shareholders in real time.</p> <p>3. Paragraph 3 is hereby</p>

Article	After revision	Before Revision	Description
	<p><u>via video conference shall re-register their attendance with the Company in accordance with the regulations.</u></p> <p>(Omitted below)</p>	(Omitted below)	revised, to prescribe that in the event of the Company's convening a shareholders meeting separately via a tentative resolution, shareholders that intend to attend the meeting via video conference shall register such attendance with the Company.
Article 11	<p>(Speeches by shareholders) (1. to 6. omitted)</p> <p><u>When convening a virtual shareholders meeting, shareholders attending via video conference may raise questions via text on the shareholders meeting video conferencing platform, beginning once the chair declares the meeting open, and continuing until the chair declares the meeting adjourned. No more than two questions for the same proposal may be raised. Each question shall contain no more than 200 words. The provisions of Paragraphs 1 to 5 shall not apply.</u></p>	(Speeches by shareholders) (1. to 6. omitted)	Paragraph 7 is hereby added to clearly prescribe the method, procedure, and restrictions on the questions raised by shareholders attending the virtual shareholders meeting.
Article 19	<p><u>When convening a virtual shareholders meeting, the Company shall, immediately after the voting is closed, disclose the voting results of all proposals and election results on the shareholders meeting video conferencing platform in accordance with regulations, and shall continue to disclose them for at least 15 minutes after the chair declares the meeting adjourned.</u></p>	These Rules shall take effect after having been submitted to and approved by the Shareholders Meeting, and subsequent revisions thereof shall be effected in the same manner.	<ol style="list-style-type: none"> 1. This article is hereby added, to allow shareholders attending the meeting via video conference the opportunity to be informed of the voting status and election results for each proposal in real time. 2. The original Article 19 is hereby relocated to Article 21.

Article	After revision	Before Revision	Description
Article 20	<p><u>When convening a virtual shareholders meeting where the video conferencing platform or the participation therein by video conference is disrupted continuously for 30 minutes or more due to natural disasters, accidents or other force majeure events before the chair declares the meeting adjourned, the meeting shall be postponed or resumed within five days, and Article 182 of the Company Act shall not apply.</u></p> <p><u>When convening a hybrid shareholders meeting where the meeting held via video conference cannot be continued as provided in Paragraph 1, if the total number of shares represented by the shareholders in attendance after deducting the number of shares represented by the shareholders in attendance via videoconference still meets the quorum for holding a shareholders meeting, the shareholders meeting shall still proceed, and need not be postponed or resumed in accordance with the provisions of Paragraph 1.</u></p>	(Newly added)	This article is hereby added to prescribe that, if a shareholders meeting is convened virtually; the chair has announced the meeting open; the video conferencing platform or the participation therein via video conference is then disrupted due to natural disasters, accidents or other force majeure events; and the disruption persists and cannot be eliminated for 30 minutes or more, then the meeting must be postponed or resumed on a date within five days. Article 182 of the Company Act requiring the adoption of a resolution by the shareholders meeting for this purpose shall then not apply.
Article 21	<u>These Rules shall take effect after having been submitted to and approved by the Shareholders Meeting, and subsequent revisions thereof shall be effected in the same manner.</u>	(Newly added)	The original Article 19 is hereby relocated to Article 21.